N-(4-Hydroxyphenyl)retinamide and nitric oxide pro-drugs exhibit apoptotic and anti-invasive effects against bone metastatic breast cancer cells

Carcinogenesis

Volumn 27, Issue 3, 2006, Pages 568-577

  Simeone, Ann Marie ^a   Colella, Stefano ^a   Krahe, Ralf ^a   Johnson, Marcella M ^a   Mora, Edna ^b   Tari, Ana M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF PUERTO RICO   (Puerto Rico)

Author keywords

[No Author keywords available]

Indexed keywords

FENRETINIDE; GELATINASE B; ILOMASTAT; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CELL; CANCER INVASION; CELL GROWTH; CELL STRAIN; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SENSITIVITY; ENZYME ACTIVITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANTICARCINOGENIC AGENTS; APOPTOSIS; BONE NEOPLASMS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INDUCTION; FEMALE; FENRETINIDE; HUMANS; HYDRAZINES; NEOPLASM INVASIVENESS; NITRIC OXIDE; NITRIC OXIDE DONORS; NITRIC OXIDE SYNTHASE; NITROGEN OXIDES; TUMOR CELLS, CULTURED;

EID: 33644868276     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgi233     Document Type: Article

References (39)

1. Coleman,R.E. and Rubens,R.D. (1987) The clinical course of bone metastases from breast cancer. Br. J. Cancer, 55, 61-66.
2. Aaron,A.D. (1994) The management of cancer metastatic to bone. JAMA, 272, 1206-1209.
3. Weiss,L. (1992) Comments on hematogenous metastatic patterns in humans as revealed by autopsy. Clin. Exp. Metastasis, 10, 191-199.
4. Gauthier,N., Lohm,S., Touzery,C., Chantome,A., Perette,B., Reveneau,S., Brunotte,F., Juillerat-Jeanneret,L. and Jeannin,J.-F. (2004) Tumour-derived and host-derived nitric oxide differentially regulate breast carcinoma metastasis to the lungs. Carcinogenesis, 25, 1559-1565.
5. Thomsen,L.L., Miles,D.W., Happerfield,L., Bobrow,L.G., Knowles,R.G. and Moncada,S. (1995) Nitric oxide synthase activity in human breast cancer. Br. J. Cancer, 72, 41-44.
6. Tschugguel,W., Schneeberger,C., Unfried,G., Czerwenka,K., Weninger,W., Mildner,M., Gruber,D.M., Sator,M.O., Waldhor,T. and Huber,J.C. (1999) Expression of inducible nitric oxide synthase in human breast cancer depends on tumor grade. Breast Cancer Res. Treat., 56, 145-151.
7. Vakkala,M., Kahlos,K., Lakari,E., Paakko,P., Kinnula,V. and Soini,Y. Inducible nitric oxide synthase expression, apoptosis, and angiogenesis in in situ and invasive breast carcinomas. Clin. Cancer Res., 6, 2408-2416.
8. Xu,W., Liu,L., Smith,G.C. and Charles,G. (2000) Nitric oxide upregulates expression of DNA-PKcs to protect cells from DNA-damaging anti-tumour agents. Nat. Cell Biol., 2, 339-345.
9. Orucevic,A., Bechberger,J., Green,A.M., Shapiro,R.A., Billiar,T.R. and Lala,P.K. (1999) Nitric-oxide production by murine mammary adenocarcinoma cells promotes tumor-cell invasiveness. Int. J. Cancer, 81, 889-896.
10. Jadeski,L.C., Hum,K.O., Chakraborty,C. and Lala,P.K. (2000) Nitric oxide promotes mammary tumor growth and metastasis by stimulating tumour cell migration, invasiveness and angiogenesis. Int. J. Cancer, 86, 30-39.
11. Bani,D., Mansini,E., Bello,M.G., Bigazzi,M. and Sacchi,T.B. (1995) Relaxin activates the L-arginine-nitric oxide pathway in human breast cancer cells. Cancer Res., 55, 5272-5275.
12. Adami,A., Crivellente,F., De Prati,A.C., Cabalieri,E., Cuzzolin,L., Tommasi,M., Suzuki,H. and Benoni,G. (1998) Biotransformation and cytotoxic properties of NO-donors on MCF7 and U251 cell lines. Life Sci., 63, 2097-2105.
13. Binder,C., Schulz,M., Hiddemann,W. and Oellerich,M. (1999) Induction of inducible nitric oxide synthase is an essential part of tumor necrosis factor-(-induced apoptosis in MCF-7 and other epithelial tumor cells. Lab. Invest., 79, 1703-1712.
14. Umansky,V., Ushmorov,A., Ratter,F., Chlichlia,K., Bucur,M., Lichtenauer,A. and Rocha,M. (2000) Nitric oxide-mediated apoptosis in human breast cancer cells requires changes in mitochondrial functions and is independent of CD95(APO-1/Fas). Int. J. Oncol., 16, 109-117.
15. Simeone,A., Ekmekcioglu,S., Broemeling,L.D., Grimm,E.A. and Tari,A.M. (2002) A novel mechanism by which N-(4-hydroxyphenyl) retinamide inhibits breast cancer cell growth: The production of nitric oxide. Mol. Cancer Ther., 1, 1009-1017.
16. Hussain,S.P., Hofseth,L.J. and Harris,C.C. (2003) Radical causes of cancer. Nat. Rev. Cancer, 3, 276-285.
17. Dong,Z., Staroselsky,A.H., Qi,X., Xie,K. and Fidler,I.J. (1994) Inverse correlation between expression of inducible nitric oxide synthase activity and production metastasis in K-1735 murine melanoma cells. Cancer Res., 54, 789-793.
18. Dhar,A., Brindley,J.M., Stark,C., Citro,M.L., Keefer,L.K. and Colburn,N.H. (2003) Nitric oxide does not mediate but inhibits transformation and tumor phenotype. Mol. Cancer Ther., 2, 1285-1293.
19. Le,X., Wei,D., Huang,S., LancasteI,J.R. and Xie,K. (2005) Nitric oxide synthase II suppresses the growth and metastasis of human cancer regardless of its upregulation of protumor factors. Proc. Natl Acad. Sci. USA, 102, 8758-8763.
20. Um,S.-J., Lee,S.-Y., Kim,E.-J., Han,H.-S., Koh,Y.-M., Hong,K.-J., Sin,H.-S. and Park,J.-S. (2001) Antiproliferative mechanism of retinoid derivatives in ovarian cancer cells. Cancer Lett., 174, 127-134.
21. Kim,J.H., Tanabe,T., Chodak,G.W. and Rukstalis,D.B. (1995) In vitro anti-invasive effects of N-(4-hydroxyphenyl)-retinamide on human prostatic adenocarcinoma. Anticancer Res., 15, 1429-1434.
22. Webber,M.M., Bello-DeOcampo,D., Quader,S., Deocampo,N.D., Metcalfe,W.S. and Sharp,R.M. (1999) Modulation of the malignant phenotype of human prostate cancer cells by N-(4-hydroxyphenyl) retinamide (4-HPR). Clin. Exp. Metastasis, 17, 255-263.
23. Quader,S.T.A., Bello-DeOcampo,D., Williams,D.E., Kleinman,H.K. and Webber,M.M. (2001) Evaluation of the chemopreventive potential of retinoids using a novel in vitro human prostate carcinogenesis model. Mutat. Res., 496, 153-161.
24. Sharp,R.M., Bello-DeOcampo,D., Quader,S.T.A. and Webber,M.M. (2001) N-(4-hydroxyphenyl)retinamide (4-HPR) decreases neoplastic properties of human prostate cells: An agent for prevention. Mutat. Res., 496, 163-170.
25. Ferrari,N., Morini,M., Pfeffer,U., Minghelli,S., Noonan,D.M. and Albini,A. (2003) Inhibition of Kaposi's sarcoma in vivo by fenretinide. Clin. Cancer Res., 9, 6020-6029.
26. Saavedra,J.E., Shami,P.J., Wang,L.Y., Davies,K.M., Booth,M.N., Citro,M.L. and Keefer,L.K. (2000) Esterase-sensitive nitric oxide donors of the diazeniumdiolate family. In vitro antileukemic activity. J. Med. Chem., 43, 261-269.
27. Brunner,N., Thompson,E.W., Spang-Thomsem,M., Rygaard,J., Dano,K. and Zwiebel,J.A. (1992) 1acZ transduced human breast cancer xenografts as an in vivo model for the study of invasion and metastasis. Eur. J. Cancer, 28A, 1989-1995.
28. Yoneda,T., Williams,P.J., Hiraga,T., Niewolna,M. and Nishimura,R. (2001) A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. J. Bone Min. Res., 16, 1486-1495.
29. Formelli,F., Clerici,M., Campa,T., Di Mauro,M., Magni,A., Mascotti,G., Moglia,D., De Palo,G., Costa,A. and Veronesi,U. (1993) Five-year administration of fenretinide: Pharmacokinetics and effects on plasma retinol concentrations. J. Clin. Oncol., 11, 2036-2042.
30. Hagemann,T., Robinson,S.C., Schulz,M., Trumper,L., Balkwill,F.R. and Binder,C. (2004) Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent upregulation of matrix metalloproteases. Carcinogenesis, 25, 1543-1549.
31. Simeone,A., Broemeling,L.D., Rosenblum,J. and Tari,A.M. (2003) HER2/neu reduces the apoptotic effects of N-(4-hydroxyphenyl)retinamide (4-HPR) in breast cancer cells by decreasing nitric oxide production. Oncogene, 22, 6739-6747.
32. Balduyck,M., Zerimach,F., Gouyer,V. et al. (2000) Specific expression of matrix metalloproteases 1, 3, 9 and 13 associated with invasiveness of breast cancer cells in vitro. Clin. Exp. Metastasis, 18, 171-178.
33. Morini,M., Mottolese,M., Ferrari,N., Ghiorzo,F., Buglioni,S., Mortarini,R., Noonan,D.M., Natali,P.G. and Albini,A. (2000) The alpha 3 beta 1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity. Int. J. Cancer, 87, 336-342.
34. Weber,M.H., Lee,J. and Orr,F.W. (2002) The effect of Neovastat (AE-941) on an experimental metastatic bone tumor model. Int. J. Oncol., 20, 299-303.
35. Vaccari,M., Silingardi,P., Argnani,A., Horn,W., Giungi,M., Mascolo,M.G., Grilli,S. and Colacci,A. (2000) In vitro effects of fenretinide on cell-matrix interactions. Anticancer Res., 20, 3059-3066.
36. Diel,I.J., Solomayer,E.F., Costa,S.D., Gollan,C., Goerner,R., Wallwiener,D., Kaufmann,M. and Bastert,G. (1998) Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N. Engl. J. Med., 339, 357-363.
37. Powles,T., Paterson,S., Kanis,J.A. et al. (2002) Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J. Clin. Oncol., 20, 3219-3224.
38. Diel,I.J., Solomyer,E.F. and Bastert,G. (2000) Bisphosphonates and the prevention of metstases: Fast evidences from preclinical and clinical studies. Cancer, 88, 3080-3088.
39. Saarto,T., Blomqvist,C., Virkkunen,P. and Elomaa,I. (2001) Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J. Clin. Oncol., 19, 10-17.